investors

Press Releases

DateTitle and SummaryView
March 30, 2016
ICT-107 Phase 3 Registration Trial Underway; Collaborations to Enhance Dendritic Cell and Stem Cell Platform Progressing
ImmunoCellular Therapeutics Announces 2015 Financial Results
March 29, 2016
LOS ANGELES , March 29, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for 2015 on Wednesday, March 30, 2016 . The Company also plans to hold a conference call and webcast on that day at 5:00 pm
ImmunoCellular Therapeutics to Report 2015 Financial Results on March 30, 2016
March 7, 2016
LOS ANGELES , March 7, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer of ImmunoCellular , will present a corporate overview and business update at the 28 th Annual ROTH Conference on
ImmunoCellular Therapeutics to Present at ROTH Conference on March 16, 2016
February 16, 2016
LOS ANGELES , Feb. 16, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell
ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program
February 1, 2016
LOS ANGELES , Feb. 1, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos , Chief Executive Officer, will present a corporate overview and business update at the 18 th Annual BIO CEO & Investor Conference at 2:00 pm ET on
ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 8, 2016
January 27, 2016
LOS ANGELES , Jan. 27, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Eduardo Davila , PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School
ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms
December 14, 2015
LOS ANGELES , Dec. 14, 2015 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium (CBTC), for the phase 3 registrational trial of
ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma
December 7, 2015
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NEW YORK , Dec. 7, 2015 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC), today announced that the December 3
ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing
December 7, 2015
LOS ANGELES , Dec. 7, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with a major cancer research group, Alliance Foundation Trials, LLC (AFT), for the phase 3 registrational trial of its cancer
ImmunoCellular Therapeutics Establishes Agreement with Alliance Foundation Trials, LLC for ICT-107 Phase 3 Registrational Trial in Glioblastoma
December 1, 2015
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NEW YORK , Dec. 1, 2015 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos ,
ImmunoCellular Therapeutics to Webcast, Live, at VirtualInvestorConferences.com December 3
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved